Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2011

View Archived Issues

RVX-208 does not significantly raise ApoA-I levels in ASSERT trial

Overall success rate of clinical drug development is 9%

Taiwanese scientists use [18F]-FDG PET to predict survival of patients with OSCC

Antiestrogen therapy for breast cancer may reduce risk of mortality from lung cancer

Vernalis presents new inhibitors of serine/threonine-protein kinase Chk1

Astellas reviews highlights of third quarter fiscal year 2010

New cytotoxic chalcone derivatives claimed by Adamed

Pfenex and Boehringer Ingelheim form strategic alliance for novel technology

Eli Lilly achieves milestone in Mirror Portfolio venture

New modulators claimed of metabotropic glutamate mGlu4 receptor

Irish scientists patent new metal complexes for cancer therapy

GSK divulges new agents for treatment of HIV infections

INTERCEPT-prepared plasma receives FDA orphan drug status in TTP

Endo Pharma and Bioniche begin enrollment in second phase III trial of Urocidin

Aeolus receives U.S. government contract to develop AEOL-10150 for lung ARS

Spanish Ministry of Health grants full reimbursement for Sativex in MS-related spasticity

Rockwell Medical initiates PRIME trial examining use of SFP in hemodialysis

PharmaGap contracts NLI to develop liposomal GAP-107B8 formulation

Astellas and Aveo sign agreement for tivozanib outside of Asia

NICE recommends use of Vidaza for treatment of MDS and AML

Pro-Pharma receives final tranche from QTDP grant

Enrollment begins in phase II trial of carboplatin and paclitaxel plus Reolysin in pancreatic cancer

Phase III Chinese trial of Dromos in peripheral arterial diseases meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...